Madrigal Pharmaceuticals, Inc.
Clinical trials sponsored by Madrigal Pharmaceuticals, Inc., explained in plain language.
-
New pill shows promise for genetic high cholesterol
Disease control CompletedThis study tested an experimental drug called MGL-3196 in 116 adults with a genetic condition that causes very high cholesterol (heterozygous familial hypercholesterolemia). The goal was to see if the drug could lower bad cholesterol (LDL-C) more than a placebo over 12 weeks. The…
Phase: PHASE2 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:15 UTC
-
New pill shows promise in cutting liver fat for NASH patients
Disease control CompletedThis study tested a daily pill called MGL-3196 in 125 adults with a serious liver disease called NASH (non-alcoholic steatohepatitis). The main goal was to see if the drug could reduce liver fat after 12 weeks compared to a placebo. The trial was completed and measured safety and…
Phase: PHASE2 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:14 UTC
-
Kidney study tests drug safety in severe cases
Knowledge-focused CompletedThis study looked at how the drug resmetirom is processed in people with severe kidney impairment compared to healthy people. 28 participants took 100 mg of resmetirom daily for 6 days. The goal was to measure drug levels in the blood and check for side effects, helping doctors u…
Phase: PHASE1 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated May 01, 2026 15:57 UTC